photo walkheader_zpsd5bunpmi.png

Unfolding: Gemcitabine + Abraxane + Cisplatin for Stage 4 Pancreatic Cancer

Since the mid-1990s, teams affiliated with Dr. Daniel Von Hoff have ushered in two of the three key advances in the first-line treatment of advanced pancreatic cancer (ductal adenocarcinoma of the pancreas). This includes seminal work from a research institute affiliated with the University of Texas at San Antonio on the development of gemcitabine for the treatment of pancreatic cancer, AND per published article in 2013 as acting lead of an international consortium presenting the MPACT study results that represented a formal introduction to the advantages of gemcitabine plus Abraxane (nab-paclitaxel) in the treatment of metastatic pancreatic cancer. The other key advance was the 2011 article in the New England Journal of Medicine by French researchers demonstrating the survival advantage of the 4-drug regimen known as FOLFIRINOX over gemcitabine alone in the therapy for advanced pancreatic cancer.

Now another treatment improvement from a new Von Hoff team that appears, at least thus far, to offer potential further increased survival advantage. First in the April 2015 American Association for Cancer Research (AACR) annual meeting, and later at the January 2017 Gastrointestinal Cancers Symposium (American Society of Clinical Oncology – ASCO) Von Hoff’s team from HonorHealth Research Institute in Scottsdale, Arizona and other institutions, including fellow researchers Gayle S. Jameson, Erkut Borazanci and other authors, have reported out the rolling results of an ongoing Phase Ib/II clinical trial that assess the addition of cisplatin to the original gemcitabine plus Abraxane regimen in the treatment of metastatic pancreatic cancer (clinical trial: NCT01893801).

In the 2015 AACR meeting, the researchers published their work in a meeting abstract entitled, “High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer.” Under the rationale that pancreatic cancer not infrequently demonstrates abnormalities in DNA repair that may tend to respond to such entities as platinum salts, they added cisplatin to the gemcitabine plus Abraxane chemotherapy regimen for patients with stage IV pancreatic cancer. Ten patients with advanced pancreatic cancer were enrolled with two showing a complete response, six showing a partial response, one offering stable disease, and one demonstrating progression of their pancreatic cancer. Four patients had serious adverse side effects including sepsis/pneumonia, bacteremia, clostridium difficile colitis, and neutropenic fever/pneumonia. Despite the sobering events profile, the clinical results were encouraging enough for the researchers to move forward to the stage II status of the clinical trial.

In the 2017 Gastrointestinal Cancers Symposium, the research team both published an abstract and presented their further results in a Poster Presentation, “A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients with stage IV pancreatic cancer.” The 25 patients in three U.S. sites met inclusion criteria including being diagnosed with stage IV pancreatic cancer between December 2013 and July 2016. All of the patients were treated with the three-drug regimen. 20% had their tumor resected. 18 of the 25 patients had a greater than 30% reduction in the pancreatic cancer tumor size. The median survival to date (at the time of presentation) was 16.5 months, with 20% alive at 24 months. 40% of the patients experienced a grade 4 adverse effect including primarily such conditions as thrombocytopenia, anemia, neutropenia, infection, or substantive diarrhea.

Dr. Erkut Borazanci indicated that there appears to be, “something related to ‘BRCA-ness’ in pancreatic tumors,” referring to the positive response that patients with BRCA1 or BRCA2  genetic-mutation-related cancers tend to have to platinum drugs (and perhaps PARP inhibitors). Please note our Pancreatica Blog on this topic Here.

These preliminary survival outcome results with the cisplatin + gemcitabine + Abraxane regimen for advanced pancreatic cancer are remarkably encouraging, to say the least. The adverse effects of this chemotherapy regimen though are rather profound, and would require serious management and care. One interesting finding was the high number of patients who became available for surgery during the course of the treatment (the authors have indicated that a separate study of this outcome is anticipated). It is important to note that these are meeting results with a small number of patients, and the results are not yet published in a peer-reviewed journal. It will be highly interesting to see if the outcomes of this treatment approach hold up in a Phase III trial, and as peer reviewed. If so, the current Von Hoff team will have again succeeded in changing the landscape of the treatment for advanced pancreatic cancer.

 

References
Proceedings: AACR 106th Annual Meeting; April 18-22, 2015; Philadelphia, PA; Cancer Res 2015;75(15 Suppl):Abstract LB-003. doi:10.1158/1538-7445.

2017 Gastrointestinal Cancers Symposium, ASCO, San Francisco; J Clin Oncol 35, 2017 (suppl 4S; abstract 341); Poster Session B Board #F11.

 

Dale O’Brien, MD

 

FOLFIRINOX vs. Gemcitabine plus Abraxane for Advanced Pancreatic Cancer

Every person is different; every situation is different; every cancer is different. So, the decision about which treatment is right for an individual patient with pancreatic cancer (ductal adenocarcinoma of the pancreas) by their health care team is highly complex. Here we present the work of published research that examines factors related to two of the most common chemotherapy regimens in use for advanced stage pancreatic cancer.

A December 2016 study in the World Journal of Gastroenterology by Kattan et al. compared information from the phase III clinical trial reported out in the New England Journal of Medicine article in 2011 that measured the 4-drug FOLFIRINOX regimen favorably against the use of gemcitabine alone in metastatic pancreatic cancer WITH information from the phase III clinical trial reported out in the New England Journal of Medicine article in 2013 that measured gemcitabine plus Abraxane favorably against the use of gemcitabine alone in metastatic pancreatic cancer. The authors addressed such topics as study design, efficacy, toxicity, effects on quality of life, and the cost effectiveness of these two regimens, based on these two key studies.

 

TRIAL DESIGN
In general, patients with pancreatic cancer who received FOLFIRINOX were somewhat younger and more robust, on balance, than those from the gemcitabine + Abraxane trial (the FOLFIRINOX study used ECOG standards, and the gemcitabine + Abraxane study used Karnofsky measures). These factors could have skewed the results in the latter trial to more side effects and toward reduced clinical response rates. This is a very important point to keep in mind in considering these studies.

Characteristic             FOLFIRINOX                G + Abraxane
Duration                      2005 – 2009                  2009 – 2012
# Patients                          171                                    431
Location                          France                           multinational
Age, min-med-max     25-61-76                             27-62-86
Performance status     37-62-1                               16-77-7

 

EFFICACY
The FOLFIRINOX study in regard to its cohort appeared to show better efficacy in comparison to the pancreatic cancer patient cohort in the gemcitabine + Abraxane study. This latter study included patients from North America, Australia, and Eastern and Western Europe. A subgroup analysis of Canadians in this study demonstrated an overall pancreatic cancer survival duration of 11.9 months, pointing to possible outcome differences between countries involved.

Characteristic                     FOLFIRINOX                    G + Abraxane
Overall Response Rate          31.6%                                        23%
PR                                              31%                                         23%
SD                                             38.6%                                       27%
DCR                                          70.2%                                        48%
PFS1/2 (mos)                            6.4                                            5.5
OS1/2 (mos)                            11.1                                           8.5
1-yr Overall Survival              48.4%                                        35%

 

TOXICITY & QUALITY of LIFE
For the first two months of treatment, the FOLFIRINOX study seemed to show improved overall patient health status by relieving several pancreatic cancer symptoms (except diarrhea). The Gemcitabine + Abraxane study did not assess quality of life, but the regimen appeared to improve quality-adjusted survival in metastatic pancreatic cancer compared to the use of gemcitabine alone.

Adverse Event                    FOLFIRINOX                    G +Abraxane
Neutropenia                               45.7%                                   38%
Thrombocytopenia                    9.1%                                     13%
Anemia                                        7.8%                                     13%
Fatigue                                       23.6%                                     17%
Peripheral Neuropathy             9%                                         17%
Diarrhea                                     12.7%                                      6%
Alopecia (grade 2)                     11.4%                                    50%

 

COST
Here we use 2014 Medicare average sales prices for the three pancreatic cancer treatment regimens. The bottom row assumes that patients continued until progression per key study results (each with their own unique demographics). The UK’s National Health Service has rejected Abraxane due to cost.

Cost                           Gemcitabine            FOLFIRINOX               G + Abraxane
Monthly Cost               $1,363                       $7,234                       $12,221
PFS1/2 (mos)                 3.7                              6.4                                5.5
Cost to progression    $5,043                      $46,298                      $67,216

 

SUMMARY
Both FOLFIRINOX and Gemcitabine plus Abraxane improve the duration of survival compared to gemcitabine, which had been the standard of care for advanced pancreatic cancer. It is difficult to compare these drug regimens as the patient populations are different and, to date, no study has done a direct comparison in pancreatic cancer. But this idea of comparing the Phase III clinical trial results of the two treatment regimens is a very clever one by Kattan and colleagues. Until more direct data are available, one has the sense from comparisons such as this, that FOLFIRINOX may offer slightly better efficacy, with comparable or possibly slightly more intense side effects. But direct comparative data are not yet available. So, as Paul Simon says, we are left with “hints and allegations” until that time. The costs of these regimens for advanced pancreatic cancer are surprisingly high.

More Here
More Here
More Here
More Here

David Dessert

Neoadjuvant Therapy in Stage 3 Pancreatic Cancer Confers Survival Advantage

In a certain sense, treatment selection by professionals is easier in early or late stage pancreatic cancer (ductal adenocarcinoma of the pancreas) because the options tend to be narrower: early yields surgery; late leans toward chemotherapy alone. The middle stages II and III, or locally advanced, potentially resectable pancreatic cancer, etc. tend to be more problematic in terms selecting the optimal course of action among the array of initial treatment options. The term that Farnell, et al. use for assessing this treatment option situation in the article reviewed is “poorly defined.”

The authors, all from the surgical service at the Mayo Clinic in Rochester, Minnesota, retrospectively reviewed a nine-year period beginning in 2002 for the outcome of survival duration in patients with stage 3 pancreatic cancer in the U.S. National Cancer Data Base, dividing them into those who received neoadjuvant therapy as the initial treatment modality with an intention for subsequent pancreatic cancer surgery, or as having received surgery first with adjuvant therapy to come later. The results were published in the October 2016 issue of the journal Surgery.

Almost 600 patients in these two categories were identified, about two-thirds in the neoadjuvant pancreatic cancer group and the rest in the surgery first group. However, over a quarter of the neoadjuvant patients were unable to receive pancreatic cancer surgery due to preoperative attrition, leaving 273 patients who were able to undergo both neoadjuvant therapy and pancreatic surgery. In the surgery first group approaching 14% of patients did not receive adjuvant therapy leaving 186 patients with pancreatic cancer who received both modalities.

The overall survival of these two groups with pancreatic cancer was 20.7 months for the neoadjuvant therapy group, and 13.7 months for the surgery first group (P = .0012).

This is an impressive survival advantage for state 3 patients with pancreatic cancer receiving neoadjuvant therapy prior to surgery, although the high rate of those unfortunately unable to ultimately receive the planned surgery is noted.  This is a commendable and good step forward in trying to provide illuminating light in the otherwise somewhat murky area of the optimal treatment strategy for the presenting middle stages of pancreatic cancer. More research in this area is needed, including teasing out options for different circumstances, and ultimately involving prospective studies.

 

The Article Reviewed

 

Dale O’Brien, MD

Page 2 of 3912345...102030...Last »
Facebook
Facebook